RE:Conference CallYou obviously haven't understood what has been posted ad nauseum on the biomarker selected for the Phase 3 metastatic breast cancer study. The biomarker is progression free survival - PFS.
PFS is an advanced biomarker driven surrogate endpoint that the FDA has recently guided on in granting an accelerated approval - as opposed to ORR which is was the standard measurement.
And your tylenol remark suggests that you haven't kept up with the rest.